The effect of kidney volume estimation on dosimetry in lutetium-177 DOTATATE therapy.
Affiliation
Department of Nuclear Medicine (CMPE), The Christie NHS Foundation Trust, ManchesterIssue Date
2018-03-09
Metadata
Show full item recordAbstract
The kidneys are the dose-limiting organ in lutetium-177 DOTATATE therapy. Therefore, it is advisable to perform critical organ dosimetry focussed on renal dose in treated patients. A key uncertainty in such dose estimates is the use of standard phantoms to represent the individual patient. The primary aim of this study was to investigate the accuracy of methods for estimating kidney size, and hence absorbed kidney dose, by comparison with individual measurements from computed tomography (CT) imaging.Citation
The effect of kidney volume estimation on dosimetry in lutetium-177 DOTATATE therapy. 2018, Nucl Med CommunJournal
Nuclear Medicine CommunicationsDOI
10.1097/MNM.0000000000000821PubMed ID
29528911Type
ArticleLanguage
enISSN
1473-5628ae974a485f413a2113503eed53cd6c53
10.1097/MNM.0000000000000821
Scopus Count
Collections
Related articles
- The Bad Berka dose protocol: comparative results of dosimetry in peptide receptor radionuclide therapy using (177)Lu-DOTATATE, (177)Lu-DOTANOC, and (177)Lu-DOTATOC.
- Authors: Schuchardt C, Kulkarni HR, Prasad V, Zachert C, Müller D, Baum RP
- Issue date: 2013
- Peptide receptor radionuclide therapy with (177)Lu labeled somatostatin analogs DOTATATE and DOTATOC: contrasting renal dosimetry in the same patient.
- Authors: Kulkarni HR, Schuchardt C, Baum RP
- Issue date: 2013
- 177Lu-[DOTA0,Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: Analysis of dosimetry with impact on future therapeutic strategy.
- Authors: Garkavij M, Nickel M, Sjögreen-Gleisner K, Ljungberg M, Ohlsson T, Wingårdh K, Strand SE, Tennvall J
- Issue date: 2010 Feb 15
- Kidney dosimetry during <sup>177</sup>Lu-DOTATATE therapy in patients with neuroendocrine tumors: aspects on calculation and tolerance.
- Authors: Sandström M, Garske-Román U, Johansson S, Granberg D, Sundin A, Freedman N
- Issue date: 2018 Apr
- Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE.
- Authors: Ilan E, Sandström M, Wassberg C, Sundin A, Garske-Román U, Eriksson B, Granberg D, Lubberink M
- Issue date: 2015 Feb